BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Plone.org//NONSGML plone.app.event//EN
X-WR-TIMEZONE:Europe/Berlin
BEGIN:VEVENT
SUMMARY:Prof. Michael Booth\, University College London: Nucleic acid conj
 ugates: remote control\, targeting\, and entirely new functions
DTSTART;TZID=Europe/Berlin:20250401T090000
DTEND;TZID=Europe/Berlin:20250401T100000
DTSTAMP:20260614T033321Z
UID:83a4f3618e7446d6b9c4520d5fb13ddf@www2.hrz.uni-marburg.de
CREATED:20241205T125047Z
DESCRIPTION:https://www2.hrz.uni-marburg.de/en/synmikro/grk2937/whats-on/d
 ates-and-events/grk2937_speaker-series_michael-booth\nSpeaker Series. Abst
 ract: We are entering the age of nucleic acid (DNA/RNA) technologies. DNA 
 and RNA form the basis for many therapeutic and experimental technologies\
 , including gene editing and silencing\, several aspects of nanotechnology
 \, aptamers and their applications\, and cell-free gene expression. Howeve
 r\, their application is limited by the chemistry of nucleic acids. A majo
 r goal of the Booth group is the generation of nucleic acid conjugates to 
 overcome current major challenges in their delivery and targeting\, and to
  produce entirely new functions to increase their therapeutic potential. C
 ontrolling nucleic acid function would greatly expand their application in
  biology and medicine\, by reducing toxic on/off-target effects. To this e
 nd\, we have generated remote-controlled nucleic acids under the control o
 f orthogonal wavelengths of light (JACS\, Chem. Sci.) and magnetism (BioRx
 iv). These controllable nucleic acids have also been applied in synthetic 
 cells to control their communication with living cells (Nat. Chem. Biol.).
  Antisense oligonucleotides\, short single stranded synthetic oligos\, are
  the predominant form of nucleic acid therapeutics in the clinic. However\
 , despite their success\, approved ASOs target a narrow spectrum of diseas
 es and their key mechanisms of action are predominantly localised within t
 he nucleus. We have attached a nuclear importer to improve their activity 
 in the nucleus (ChemRxiv) and developed a new mechanism of action for targ
 eted mRNA degradation in the cytoplasm (unpublished). These nucleic acid c
 onjugates will form the basis of a whole new suite of targeted therapeutic
 s and technologies for basic research.
LAST-MODIFIED:20250221T170652Z
LOCATION:SYNMIKRO Lecture Hall
URL:https://www2.hrz.uni-marburg.de/en/synmikro/grk2937/whats-on/dates-and
 -events/grk2937_speaker-series_michael-booth
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Berlin
X-LIC-LOCATION:Europe/Berlin
BEGIN:DAYLIGHT
DTSTART:20250330T030000
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR